NLA 103
Alternative Names: Natural killer cell therapy - Nohla Therapeutics; NK cells/ donor lymphocyte infusion - Nohla Therapeutics; NK cells/DLILatest Information Update: 28 Feb 2021
At a glance
- Originator Nohla Therapeutics
- Developer Fred Hutchinson Cancer Research Center; Nohla Therapeutics
- Class Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer(Second-line therapy or greater) in USA
- 10 Jan 2017 Preclinical trials in Cancer (Second-line therapy or greater) in USA (unspecified route)